Photo of Andrea Necchi from www.hsr.it
Apr 28, 2024, 19:14
Andrea Necchi: Pleased to see the interim results of SURE01 trial slated for presentation at ASCO24
Andrea Necchi, Associate Professor at Vita-Salute San Raffaele University, shared on LinkedIn:
“Very pleased to see the interim results of SURE01 trial (neoadjuvant sacituzumab govitecan prior to cystectomy in MIBC) slated for presentation at ASCO24 with preliminary biomarkers and bladder-saving results.”
Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results
Authors: Antonio Cigliola, Marco Moschini, Valentina Tateo, Chiara Mercinelli, Damiano Patanè, Emanuele Crupi, Renzo Colombo, Vincenzo Scattoni, Giorgio Brembilla, Maurizio Colecchia, Francesco Montorsi, and Andrea Necchi
Source: Andrea Necchi/LinkedIn
Andrea Necchi
Antonio Cigliola
ASCO
ASCO24
cancer
Chiara Mercinelli
Damiano Patanè
Emanuele Crupi
Francesco Montorsi
Giorgio Brembilla
Marco Moschini
Maurizio Colecchia
MIBC
muscle invasive bladder cancer
OncoDaily
Oncology
Renzo Colombo
Sacituzumab govitecan
SURE01 trial
Valentina Tateo
Vincenzo Scattoni
Vita-Salute San Raffaele University
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14